CN101772484B - 合成(7-甲氧基-1-萘基)乙腈的新方法和在合成阿戈美拉汀中的应用 - Google Patents
合成(7-甲氧基-1-萘基)乙腈的新方法和在合成阿戈美拉汀中的应用 Download PDFInfo
- Publication number
- CN101772484B CN101772484B CN200880101738XA CN200880101738A CN101772484B CN 101772484 B CN101772484 B CN 101772484B CN 200880101738X A CN200880101738X A CN 200880101738XA CN 200880101738 A CN200880101738 A CN 200880101738A CN 101772484 B CN101772484 B CN 101772484B
- Authority
- CN
- China
- Prior art keywords
- formula
- synthesis
- compound
- methoxy
- naphthyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/14—Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种工业合成式(I)化合物的方法。本发明可用于阿戈美拉汀的合成。
Description
本发明涉及一种工业合成(7-甲氧基-1-萘基)乙腈的方法及其在工业制备阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺中的应用。
更具体地,本发明涉及一种工业合成式(I)化合物的方法:
根据本发明方法获得的式(I)化合物用于合成式(II)的阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺:
阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺具有有价值的药理学性质。
实际上,其具有双重特性,一方面其为褪黑素系统受体的激动剂,另一方面其为5-HT2c受体的拮抗剂。这些性质向其提供了在中枢神经系统中的活性,更具体地,在治疗重性抑郁症、季节性情绪失调、睡眠障碍、心血管疾病、消化系统疾病、时差综合症引起的失眠和疲劳、食欲失调和肥胖症中的活性。
欧洲专利EP 0 447 285以及欧洲专利申请EP 1 564 202描述了阿戈美拉汀、其制备及其在治疗中的用途。
鉴于该化合物的药学价值,重要的是能从经济且易得的原料出发通过有效的工业合成方法获得它,所述方法易于转移至工业规模,并以良好的产率和极高的纯度制备阿戈美拉汀。
专利EP 0 447 285描述了以八个步骤从7-甲氧基-1-四氢萘酮开始制备阿戈美拉汀,平均产率小于30%。特别地,(7-甲氧基-1-萘基)乙腈的制备包括六个反应步骤,且一旦将其转移至工业规模,实施该方法中的困难便迅速显现。
文献描述了从7-甲氧基-1-四氢萘酮开始以如下三个步骤获得(7-甲氧基-1-萘基)乙腈:在LiCH2CN的作用下,接着用DDQ(2,3-二氯-5,6-二氰基-1,4-苯醌)脱氢,最后在酸介质中脱水(合成通讯,2001,31(4),621-629)。然而,总产率是中等的(76%),特别地,用于脱氢反应中的DDQ以及第三步所需的苯回流不能满足成本和环境方面的工业要求。
专利申请EP 1 564 202描述了一种尤其有利的工业方法,所述方法从7-甲氧基-1-四氢萘酮开始只需要四个步骤,包括获得(7-甲氧基-1-萘基)乙腈的两个步骤,平均总产率大于60%。
虽然现有技术的各种合成方法描述了(7-甲氧基-1-萘基)乙腈的制备,但其中的大部分使用7-甲氧基-1-四氢萘酮作为原料,其是合成有问题的昂贵化合物。相应地,至今仍需要开发简单且可重复生产和使用其它原料的新合成路线。
申请人现已开发了一种新工业合成方法,所述方法从更廉价和更易得的原料开始以可重复生产的方式且不需要费力的纯化获得了纯度与其用作药物活性成分相当的阿戈美拉汀。
特别地,申请人现已开发了一种使用7-甲氧基-1-萘甲酸作为原料的新工业合成方法,所述方法使得可以可重复生产的方式且不需要费力的纯化获得(7-甲氧基-1-萘基)乙腈。D.Becker等在现有技术中描述了从茴香醚开始以极高的产率制备7-甲氧基-1-萘甲酸:四面体快报,27(32),3775-3776,1986。
更具体地,本发明涉及一种工业合成式(I)化合物的方法:
所述方法的特征在于将式(III)的7-甲氧基-1-萘甲酸用于反应:
其在还原剂的作用下生成式(IV)化合物:
将所述式(IV)化合物的OH官能团转化为离去基团,其与氰化试剂反应生成以固体形式分离的式(I)化合物。
在可在本发明方法中用于还原式(III)的酸的还原剂中,可提及但不意味着任何限定的是BH3、NaBH4/AlCl3、9-硼二环[3.3.1]壬烷、LiAlH4、AlH3、氢化二异丁基铝(DIBAL-H),更具体为BH3-THF。有利的是,在本发明方法中式(III)的酸的还原也可如下进行:在将式(III)的酸转化为酸衍生物,更具体为酯之后,接着使用还原剂LiAlH4、与或不与MeOH缔合的NaBH4、LiBH4、DIBAL-H或双(2-甲氧基乙氧基)-氢化铝钠(Red-Al)将该酸衍生物还原成式(IV)的醇。
有利的是,将本发明方法的式(IV)化合物的OH基团转化成卤素,更具体为溴或氯,或转化成甲苯磺酸酯、甲磺酸酯、对硝基苯磺酸酯或三氟甲磺酸酯。更优选使用三溴化硼、二氯亚砜、甲磺酰氯,甲苯磺酰氯,三氟甲磺酰氯或对硝基苯磺酰氯进行向离去基团的转化。有利的是,在二氯亚砜的作用下使式(IV)化合物的OH基团转化为氯。
在可用于本发明方法的氰化试剂中,可提及但不意味着任何限定的是氰化三甲基甲硅烷、氰化锂、氰化钠、氰化钾和氰化四丁基铵。优选的氰化试剂为氰化钾。
当需要时,将由此获得的式(I)化合物还原,然后使其与乙酸酐进行偶联反应以生成阿戈美拉汀。
实施例:(7-甲氧基-1-萘基)乙腈
步骤A:(7-甲氧基-1-萘基)甲醇
向1当量在THF(3.8ml/g)中的7-甲氧基-1-萘甲酸(100g)缓慢加入2.5当量1M的BH3-THF(1.235升)。在加入过程中,将反应混合物的温度保持在5℃(+/-2℃),然后在环境温度下将混合物静置3小时。减压蒸发后,将残留物溶解在二氯甲烷中并用水洗涤。MgSO4干燥有机相,然后减压蒸发溶剂得到淡褐色固体形式的标题化合物,产率为91%。
熔点:72-74℃
步骤B:1-(氯甲基)-7-甲氧基萘
向步骤A所得化合物(100g)在二氯甲烷(5ml/g)中的溶液加入2当量二氯亚砜(126.35g)。加热混合物至回流,并保持回流2小时。回到环境温度后,减压蒸发溶剂。将所得油溶解在乙酸乙酯中,依次用水和饱和NaCl溶液洗涤。减压蒸发溶剂,通过使其通过硅胶垫纯化粗产物(洗脱液:庚烷)。以黄色固体的形式获得标题化合物,产率为84%。
步骤C:(7-甲氧基-1-萘基)乙腈
向步骤B所得化合物(100g)在30ml/g DMSO和5ml/g水中的溶液加入1.2当量氰化钾(37.8g)。加热反应混合物至65℃,并保持在65℃下3小时。回到环境温度后,将MTBE/水(1/1)二元体系加入混合物中。去除水相。依次用水和饱和NaCl溶液洗涤有机相数次。蒸发溶剂,以定量产率获得标题化合物。
熔点:83℃。
Claims (4)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705688 | 2007-08-03 | ||
| FR0705688A FR2919606B1 (fr) | 2007-08-03 | 2007-08-03 | Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine. |
| PCT/FR2008/001146 WO2009053545A2 (fr) | 2007-08-03 | 2008-08-01 | Nouveau procede de synthese du (7-methoxy-l-naphtyl)acetonitrile et application a la synthese de l'agomelatine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101772484A CN101772484A (zh) | 2010-07-07 |
| CN101772484B true CN101772484B (zh) | 2013-09-18 |
Family
ID=38926411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880101738XA Expired - Fee Related CN101772484B (zh) | 2007-08-03 | 2008-08-01 | 合成(7-甲氧基-1-萘基)乙腈的新方法和在合成阿戈美拉汀中的应用 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8252951B2 (zh) |
| EP (1) | EP2176214B1 (zh) |
| JP (1) | JP5250626B2 (zh) |
| KR (1) | KR101179173B1 (zh) |
| CN (1) | CN101772484B (zh) |
| AP (1) | AP2611A (zh) |
| AR (1) | AR070642A1 (zh) |
| AU (1) | AU2008316406B2 (zh) |
| BR (1) | BRPI0815126A2 (zh) |
| CA (1) | CA2695234C (zh) |
| CL (1) | CL2008002272A1 (zh) |
| CY (1) | CY1115094T1 (zh) |
| DK (1) | DK2176214T3 (zh) |
| EA (1) | EA016333B1 (zh) |
| ES (1) | ES2467690T3 (zh) |
| FR (1) | FR2919606B1 (zh) |
| GE (1) | GEP20125586B (zh) |
| HR (1) | HRP20140407T1 (zh) |
| JO (1) | JO2992B1 (zh) |
| MA (1) | MA31740B1 (zh) |
| MY (1) | MY160226A (zh) |
| NZ (1) | NZ583064A (zh) |
| PA (1) | PA8792101A1 (zh) |
| PE (1) | PE20090881A1 (zh) |
| PL (1) | PL2176214T3 (zh) |
| PT (1) | PT2176214E (zh) |
| RS (1) | RS53250B (zh) |
| SA (1) | SA08290480B1 (zh) |
| SI (1) | SI2176214T1 (zh) |
| TW (1) | TWI352074B (zh) |
| UA (1) | UA94837C2 (zh) |
| UY (1) | UY31229A1 (zh) |
| WO (1) | WO2009053545A2 (zh) |
| ZA (1) | ZA201001184B (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011154140A2 (en) | 2010-06-10 | 2011-12-15 | Gador S.A. | New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide and new crystalline form |
| WO2013054273A2 (en) | 2011-10-11 | 2013-04-18 | Ranbaxy Laboratories Limited | Process for the preparation of agomelatine |
| CN103130673B (zh) * | 2011-11-28 | 2017-05-03 | 重庆医药工业研究院有限责任公司 | 一种阿戈美拉晶型i的制备方法 |
| WO2013080095A1 (en) | 2011-12-01 | 2013-06-06 | Ranbaxy Laboratories Limited | Process for the preparation of agomelatine |
| ITMI20121444A1 (it) | 2012-08-27 | 2014-02-28 | Procos Spa | Processo per la produzione di agomelatine |
| CN104788342A (zh) * | 2015-04-07 | 2015-07-22 | 湖南大学 | 一种由芳香甲醇制备芳香腈类化合物的方法 |
| CN107098828A (zh) * | 2017-05-09 | 2017-08-29 | 枣阳市残联福利生物化工厂 | 一种高效合成甲氧基萘乙腈的工艺 |
| CN107162933A (zh) * | 2017-06-19 | 2017-09-15 | 太仓大唐化纤厂 | 一种合成阿戈美拉汀重要中间体7‑甲氧基萘乙腈的方法 |
| CN107382773A (zh) * | 2017-06-19 | 2017-11-24 | 太仓弘杉环保科技有限公司 | 一种合成7‑甲氧基萘乙腈的方法 |
| CN107353229B (zh) * | 2017-08-08 | 2019-04-30 | 许昌恒生制药有限公司 | 一种阿戈美拉汀中间体的制备方法 |
| CN112574065B (zh) * | 2020-12-30 | 2022-10-28 | 宁波职业技术学院 | 一种(苯-1,3,5-三酰基)三乙腈的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680284A (zh) * | 2004-02-13 | 2005-10-12 | 瑟维尔实验室 | 阿戈美拉汀的新合成方法、新晶型及其药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02202864A (ja) * | 1989-01-31 | 1990-08-10 | Hitachi Ltd | 2,3―ジシアノ―6―ナフチルメタノール誘導体およびその製法 |
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2696453B1 (fr) * | 1992-10-02 | 1994-12-23 | Adir | Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent. |
| FR2726268B1 (fr) * | 1994-10-26 | 1996-12-06 | Adir | Nouvelles o-arylmethyl n-(thio)acyl hydroxylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent |
| FR2784375B1 (fr) * | 1998-10-12 | 2000-11-24 | Adir | Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2007
- 2007-08-03 FR FR0705688A patent/FR2919606B1/fr not_active Expired - Fee Related
-
2008
- 2008-07-16 UY UY31229A patent/UY31229A1/es not_active Application Discontinuation
- 2008-07-24 PE PE2008001252A patent/PE20090881A1/es active IP Right Grant
- 2008-08-01 CA CA2695234A patent/CA2695234C/fr not_active Expired - Fee Related
- 2008-08-01 KR KR1020107004649A patent/KR101179173B1/ko not_active Expired - Fee Related
- 2008-08-01 PA PA20088792101A patent/PA8792101A1/es unknown
- 2008-08-01 NZ NZ583064A patent/NZ583064A/en not_active IP Right Cessation
- 2008-08-01 WO PCT/FR2008/001146 patent/WO2009053545A2/fr not_active Ceased
- 2008-08-01 JP JP2010519488A patent/JP5250626B2/ja active Active
- 2008-08-01 DK DK08842551.7T patent/DK2176214T3/da active
- 2008-08-01 UA UAA201002246A patent/UA94837C2/ru unknown
- 2008-08-01 SI SI200831201T patent/SI2176214T1/sl unknown
- 2008-08-01 PT PT88425517T patent/PT2176214E/pt unknown
- 2008-08-01 CL CL2008002272A patent/CL2008002272A1/es unknown
- 2008-08-01 EA EA201000257A patent/EA016333B1/ru not_active IP Right Cessation
- 2008-08-01 GE GEAP200811699A patent/GEP20125586B/en unknown
- 2008-08-01 EP EP08842551.7A patent/EP2176214B1/fr active Active
- 2008-08-01 US US12/733,034 patent/US8252951B2/en not_active Expired - Fee Related
- 2008-08-01 CN CN200880101738XA patent/CN101772484B/zh not_active Expired - Fee Related
- 2008-08-01 TW TW097129371A patent/TWI352074B/zh not_active IP Right Cessation
- 2008-08-01 BR BRPI0815126-1A2A patent/BRPI0815126A2/pt not_active Application Discontinuation
- 2008-08-01 AR ARP080103344A patent/AR070642A1/es not_active Application Discontinuation
- 2008-08-01 HR HRP20140407AT patent/HRP20140407T1/hr unknown
- 2008-08-01 ES ES08842551.7T patent/ES2467690T3/es active Active
- 2008-08-01 MY MYPI2010000320A patent/MY160226A/en unknown
- 2008-08-01 RS RS20140155A patent/RS53250B/sr unknown
- 2008-08-01 PL PL08842551T patent/PL2176214T3/pl unknown
- 2008-08-01 AP AP2010005145A patent/AP2611A/xx active
- 2008-08-01 AU AU2008316406A patent/AU2008316406B2/en not_active Ceased
- 2008-08-02 SA SA08290480A patent/SA08290480B1/ar unknown
- 2008-08-03 JO JOP/2008/0348A patent/JO2992B1/ar active
-
2010
- 2010-02-18 ZA ZA2010/01184A patent/ZA201001184B/en unknown
- 2010-03-01 MA MA32661A patent/MA31740B1/fr unknown
-
2012
- 2012-07-30 US US13/561,421 patent/US8436206B2/en not_active Expired - Fee Related
-
2014
- 2014-05-21 CY CY20141100356T patent/CY1115094T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680284A (zh) * | 2004-02-13 | 2005-10-12 | 瑟维尔实验室 | 阿戈美拉汀的新合成方法、新晶型及其药物组合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101772484B (zh) | 合成(7-甲氧基-1-萘基)乙腈的新方法和在合成阿戈美拉汀中的应用 | |
| TWI386385B (zh) | 合成阿戈美拉汀(agomelatine)之新穎方法 | |
| US20090131719A1 (en) | Process for the synthesis of (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine | |
| US7994359B2 (en) | Process for the synthesis of (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine | |
| KR20130028134A (ko) | 아고멜라틴 중간체 및 이의 제조 방법 | |
| JP5021004B2 (ja) | アゴメラチン合成の新規な方法 | |
| JP2017504580A (ja) | アゴメラチンの合成のための新規な方法 | |
| CN102993040B (zh) | 一种合成阿戈美拉汀的新方法 | |
| HK1145830B (zh) | 合成(7-甲氧基-1-萘基)乙腈的新方法和在合成阿戈美拉汀中的应用 | |
| HK1226386A1 (zh) | 7-甲氧基-萘-1-甲醛的新的合成方法及其在阿戈美拉汀的合成中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1145830 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1145830 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 Termination date: 20210801 |






